Skip to content
Peptidepedia

CJC-1295 Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

CJC-1295 is frequently combined with other peptides to enhance its effects.

CJC-1295 + Ipamorelin

This is the most popular combination. Ipamorelin is a growth hormone secretagogue that works through the ghrelin receptor, providing a complementary mechanism to CJC-1295's GHRH pathway. Together, they produce synergistic GH release greater than either peptide alone. Typical dosing involves 100–300 mcg of each peptide administered together. See the full CJC-1295 vs ipamorelin comparison for more detail.

CJC-1295 + GHRP-6 or GHRP-2

These growth hormone-releasing peptides also work through the ghrelin pathway and can be stacked with CJC-1295. GHRP-6 notably increases appetite, which may be beneficial for those seeking to gain mass. For a comparison of these two GHRPs, see GHRP-2 vs GHRP-6.

CJC-1295 + BPC-157

Some users combine CJC-1295 with BPC-157 for enhanced recovery and healing, though this combination lacks clinical research.

When stacking, users typically reduce individual peptide doses slightly to account for synergistic effects and minimize potential side effects.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
  2. Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005.
  3. Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006.
  4. Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009.
  5. Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011.
  6. Aidsmap. Lipodystrophy study halted after patient death. 2006.
  7. World Anti-Doping Agency. The 2024 Prohibited List International Standard.
  8. FDA. CJC-1295 - Pharmacy Compounding Advisory Committee Materials. December 2024.
  9. Hone Health. Everything You Need to Know About the FDA Peptide Ban.
  10. Innerbody. CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice.
←Read the full CJC-1295 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”